Antivirals for the treatment of mild and moderate COVID-19 in South Africa
While the majority of COVID-19 cases in South Africa (SA) are mild, patients with severe COVID-19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services. Given the low vaccine uptake in SA and other low- and middle-income countries in sub-Saharan Africa, the high prevalence of comorbidities and limited healthcare system capacity, evidence-based interventions that reduce the risk of severe disease and death should be considered for implementation. Several antiviral classes have been newly developed or repurposed to treat COVID-19 early after infection to retard progression to severe disease and reduce the risk of death, particularly in the elderly and/or in patients with comorbidities. COVID-19 antivirals such as remdesivir, nirmatrelvir/ ritonavir and molnupiravir are safe and cost-effective and have received either full approval or emergency use authorisation from regulators. Using a proposed test-and-treat strategy, judicious use of antivirals could be impactful.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde - 113(2023), 12 vom: 04. Dez., Seite 33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perumal, R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7196/SAMJ.2023.v113i12.1066 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370152026 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370152026 | ||
| 003 | DE-627 | ||
| 005 | 20240327000339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240326s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7196/SAMJ.2023.v113i12.1066 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370152026 | ||
| 035 | |a (NLM)38525633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Perumal, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antivirals for the treatment of mild and moderate COVID-19 in South Africa |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a While the majority of COVID-19 cases in South Africa (SA) are mild, patients with severe COVID-19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services. Given the low vaccine uptake in SA and other low- and middle-income countries in sub-Saharan Africa, the high prevalence of comorbidities and limited healthcare system capacity, evidence-based interventions that reduce the risk of severe disease and death should be considered for implementation. Several antiviral classes have been newly developed or repurposed to treat COVID-19 early after infection to retard progression to severe disease and reduce the risk of death, particularly in the elderly and/or in patients with comorbidities. COVID-19 antivirals such as remdesivir, nirmatrelvir/ ritonavir and molnupiravir are safe and cost-effective and have received either full approval or emergency use authorisation from regulators. Using a proposed test-and-treat strategy, judicious use of antivirals could be impactful | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Naidoo, V |e verfasserin |4 aut | |
| 700 | 1 | |a Govender, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gengiah, T N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde |d 1945 |g 113(2023), 12 vom: 04. Dez., Seite 33 |w (DE-627)NLM000010618 |x 2078-5135 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2023 |g number:12 |g day:04 |g month:12 |g pages:33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7196/SAMJ.2023.v113i12.1066 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2023 |e 12 |b 04 |c 12 |h 33 | ||